Determination of perioperative levels of cefazolin in paediatric cardiac surgical patients
Completed
- Conditions
- Congenital heart disease
- Registration Number
- ACTRN12618001183279
- Lead Sponsor
- Queensland Paediatric Cardiac Services
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cefazolin's efficacy in preventing infections in congenital heart disease patients undergoing surgery?
How does cefazolin compare to other beta-lactam antibiotics in reducing postoperative infections in pediatric cardiac surgery?
Which biomarkers correlate with optimal cefazolin dosing and infection prevention in neonatal and pediatric cardiac surgical cases?
What are the potential adverse events associated with perioperative cefazolin use in pediatric congenital heart disease populations and how are they managed?
Are there combination antibiotic strategies involving cefazolin that improve outcomes in pediatric cardiac surgery compared to monotherapy?